153 related articles for article (PubMed ID: 20170097)
1. Synthesis and biological activities of 2-amino-1-arylidenamino imidazoles as orally active anticancer agents.
Li WT; Hwang DR; Song JS; Chen CP; Chuu JJ; Hu CB; Lin HL; Huang CL; Huang CY; Tseng HY; Lin CC; Chen TW; Lin CH; Wang HS; Shen CC; Chang CM; Chao YS; Chen CT
J Med Chem; 2010 Mar; 53(6):2409-17. PubMed ID: 20170097
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
3. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
4. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
Perchellet EM; Ladesich JB; Magill MJ; Chen Y; Hua DH; Perchellet JP
Anticancer Drugs; 1999 Jun; 10(5):489-504. PubMed ID: 10477169
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents.
Li WT; Hwang DR; Song JS; Chen CP; Chen TW; Lin CH; Chuu JJ; Lien TW; Hsu TA; Huang CL; Tseng HY; Lin CC; Lin HL; Chang CM; Chao YS; Chen CT
Invest New Drugs; 2012 Feb; 30(1):164-75. PubMed ID: 20890633
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of imidazol-2-one derivatives as potential antitumor agents.
Xue N; Yang X; Wu R; Chen J; He Q; Yang B; Lu X; Hu Y
Bioorg Med Chem; 2008 Mar; 16(5):2550-7. PubMed ID: 18226907
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents.
Li WT; Hwang DR; Chen CP; Shen CW; Huang CL; Chen TW; Lin CH; Chang YL; Chang YY; Lo YK; Tseng HY; Lin CC; Song JS; Chen HC; Chen SJ; Wu SH; Chen CT
J Med Chem; 2003 Apr; 46(9):1706-15. PubMed ID: 12699388
[TBL] [Abstract][Full Text] [Related]
8. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
9. BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities.
Hu CB; Chen CP; Yeh TK; Song JS; Chang CY; Chuu JJ; Tung FF; Ho PY; Chen TW; Lin CH; Wang MH; Chang KY; Huang CL; Lin HL; Li WT; Hwang DR; Chern JH; Hwang LL; Chang JY; Chao YS; Chen CT
Cancer Sci; 2011 Jan; 102(1):182-91. PubMed ID: 21040217
[TBL] [Abstract][Full Text] [Related]
10. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
11. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
Wang YM; Hu LX; Liu ZM; You XF; Zhang SH; Qu JR; Li ZR; Li Y; Kong WJ; He HW; Shao RG; Zhang LR; Peng ZG; Boykin DW; Jiang JD
Clin Cancer Res; 2008 Oct; 14(19):6218-27. PubMed ID: 18829501
[TBL] [Abstract][Full Text] [Related]
12. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells.
Chen YL; Lin SZ; Chang JY; Cheng YL; Tsai NM; Chen SP; Chang WL; Harn HJ
Biochem Pharmacol; 2006 Jul; 72(3):308-19. PubMed ID: 16782069
[TBL] [Abstract][Full Text] [Related]
14. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
15. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
Jiang JD; Denner L; Ling YH; Li JN; Davis A; Wang Y; Li Y; Roboz J; Wang LG; Perez-Soler R; Marcelli M; Bekesi G; Holland JF
Cancer Res; 2002 Nov; 62(21):6080-8. PubMed ID: 12414632
[TBL] [Abstract][Full Text] [Related]
16. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, structure elucidation and identification of antitumoural properties of novel fused 1,2,4-triazine aryl derivatives.
Sztanke K; Pasternak K; Rzymowska J; Sztanke M; Kandefer-Szerszeń M
Eur J Med Chem; 2008 May; 43(5):1085-94. PubMed ID: 17868955
[TBL] [Abstract][Full Text] [Related]
18. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of A-105972, an antineoplastic agent.
Wu-Wong JR; Alder JD; Alder L; Burns DJ; Han EK; Credo B; Tahir SK; Dayton BD; Ewing PJ; Chiou WJ
Cancer Res; 2001 Feb; 61(4):1486-92. PubMed ID: 11245455
[TBL] [Abstract][Full Text] [Related]
20. Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.
Wang X; Yuan S; Wang J; Lin P; Liu G; Lu Y; Zhang J; Wang W; Wei Y
Toxicol Appl Pharmacol; 2006 Sep; 215(2):168-78. PubMed ID: 16563451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
